Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
Universal Biosensors (ASX:UBI) is a point-of-care diagnostics developer that Endeavor Asset Management has held through its growth phase. In April 2024, Endeavor noted Universal Biosensors announced a fully underwritten $10 million capital raising at 15 cents per share, with proceeds intended to fund product pipeline activities, sales and marketing, research and development and working capital. Universal Biosensors operates in the Healthcare sector within the Healthcare Equipment and Supplies industry, and Thesis Tracker has captured 1 comment from 1 fund manager, Endeavor Asset Management. Founded in 2001 and headquartered in Rowville, Victoria, Universal Biosensors researches, develops and manufactures point-of-care diagnostic testing systems, including its Xprecia blood coagulation testing platform, Sentia wine testing system and consumer health tests, and provides contract research services to medical and industrial partners worldwide, with a focus on expanding commercial sales of its proprietary products.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Endeavor Asset Management have invested in Universal Biosensors, Inc. (ASX:UBI).
Endeavor Asset Management notes the capital raising will fund pipeline development, research and development and expanded sales and marketing, supporting commercialisation of Universal Biosensors' diagnostic products.
The need for a $10 million raise at 15 cents per share highlights the company's reliance on external funding and dilution risk for existing shareholders, as noted in Endeavor's commentary.
Universal Biosensors, Inc., founded in 2001 and headquartered in Rowville, Australia, specializes in the research, development, and manufacture of point-of-care medical diagnostic test systems. The company provides professional and home-use solutions, including blood glucose monitoring, coagulation testing, immunoassay, and molecular diagnostics. Universal Biosensors focuses on delivering diagnostic technology designed for clinical and personal healthcare applications.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.